Organometallic Iridium Arene Compounds: The Effects of C-Donor Ligands on Anticancer Activity

Rianne M. Lord, Patrick C. McGowan

Research output: Contribution to journalReview articlepeer-review

10 Citations (Scopus)

Abstract

In the past decade, libraries of iridium organometallic arene compounds have expanded rapidly, with the majority of their applications aimed towards effective catalysts and potential anti-cancer drug candidates. Researchers have begun to adapt the traditional “piano-stool” structures to include different bidentate ligands, ancillary ligands and extend the aromaticity and functionality of the arene substituent, all in the hope to optimize their activities and allow the determination of structure activity relationships. Many of the complexes incorporate N- and O-donor ligands, but more recently, these structures have been expanded to include C-donor ligands such as cyclometalated bidentate ligands and N-heterocyclic carbenes. This mini-review highlights the recent and ongoing research in C-donor iridium arene complexes, and discusses their importance as potential anticancer drugs.
Original languageEnglish
Pages (from-to)916-924
Number of pages9
JournalChemistry Letters
Volume48
Issue number8
Early online date23 May 2019
DOIs
Publication statusPublished - Aug 2019

Keywords

  • Anticancer
  • Bioinorganic chemistry
  • Iridium arene complexes
  • HALF-SANDWICH RHODIUM(III)
  • IN-VITRO CYTOTOXICITY
  • CYCLIC-PI-PERIMETER
  • BODIPY-BASED RU(II)
  • COMPLEXES SYNTHESIS
  • MOLECULAR-STRUCTURE
  • ANTITUMOR COMPLEXES
  • IR(III) COMPLEXES
  • RUTHENIUM(II) COMPLEXES
  • ESCHERICHIA-COLI

Cite this